查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863430

细胞和基因治疗药物输送装置市场（按装置类型、最终用户、产品类型、治疗方法和分销管道划分）—2025-2032年全球预测

Cell & Gene Therapy Drug Delivery Devices Market by Device Type, End User, Product Type, Therapy Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，细胞和基因治疗药物输送装置市场将成长至 25.7 亿美元，复合年增长率为 10.29%。

关键市场统计数据
基准年 2024 11.7亿美元
预计年份：2025年 12.9亿美元
预测年份 2032 25.7亿美元
复合年增长率 (%) 10.29%

一篇具有前瞻性的介绍性文章，概述了影响先进生物製药递送装置策略的技术、临床和监管方面的必要因素。

先进生物製药与精准给药装置的融合正在重塑临床医生和医疗系统应对复杂治疗方法的方式。装置工程、材料科学和连接技术的最新创新为提高细胞和基因疗法的给药精度、患者依从性和安全性创造了新的机会。同时，涉及活细胞和基因载体的临床项目对装置的兼容性、低温运输物流和无菌给药提出了严格的要求，迫使人们重新评估产品设计和操作流程。

产品开发、临床营运和商业策略的相关人员如今面临双重挑战：既要整合能够最大限度减轻终端用户负担并保持治疗效果的给药技术，又要应对日益严格的联合产品评估监管要求。这种情况使得工程师、转化科学家和监管专家需要在研发週期的早期阶段合作，多学科协作成为成功的关键因素。因此，那些优先考虑整合设备和疗法开发、完善人体工学设计以及清晰监管流程的机构，更有利于加速临床应用并扩大治疗方案的覆盖范围。

全面审视医疗器材技术、分散式医疗和监管融合等领域的关键变革趋势，这些趋势正在重新定义治疗提供方式。

由于治疗复杂性、以患者为中心的护理模式以及数位健康整合的同步发展，细胞和基因治疗递送设备的格局正在经历变革性变化。治疗研发人员越来越关注微创给药和门诊管理，这促使医疗设备製造商开发创新产品，以减少对医疗机构的依赖，例如自动注射器、无针注射器、微流体系统和穿戴式输注平台。同时，分散式医疗的趋势正在加速发展，推动了对用于敏感生物製药的医疗设备的投资增加，这些器材能够在确保监管炼和环境控制的同时，实现便捷的居家使用。

同时，为了满足个人化治疗和小批量治疗方法的需求，生产製造和供应链正变得日益复杂。微流体装置和模组化输注系统能够实现细胞产品的局部处理和即时操作，目前正在研究中，预计将缩短从采集到操作和给药的关键时间。监管机构正在调整指导方针，以应对组合产品以及医疗设备和生物製药的交叉领域，并鼓励申办方和监管机构之间进行更积极的互动。此外，设备中正在整合数位连接和远端监测功能，提供即时依从性和安全性数据，以支援治疗通讯协定的迭代改进和上市后监测。总而言之，这些变化既带来了机会，也带来了挑战，要求各组织采用整合的开发路径，并与相关人员密切合作，才能充分利用不断变化的环境。

2025年前累积关税对配送系统采购、供应商选择和製造业韧性的影响策略评估

新关税的实施对进口医疗组件和成品医疗设备造成了显着影响，对细胞和基因治疗输送系统的供应链带来了巨大压力。累积关税将持续到2025年，导致用于自动注射器、输液帮浦和一次性抛弃式产品的某些上游原料、特殊聚合物和精密组件的成本上升。因此，我们的采购部门正在审查供应商组合，探索替代来源，并重新评估总到岸成本模型，以确保专案的可行性和价格透明度。

为此，许多製造商采取了供应商多元化和尽可能将生产外包到近岸地区的双管齐下的策略，以最大限度地降低关税风险并缩短关键零件的前置作业时间。这些方法各有利弊。生产转移可以降低关税风险，但可能需要资本投资、员工培训以及对新品质系统的检验。此外，关税导致的成本增加也影响了契约製造协议的谈判和长期供应合同，因此，明确的商业条款、风险分担机制和紧急时应对计画显得尤为重要。

监管合规性和可追溯性要求增加了复杂性，因为随着采购来源的变化，医疗设备申请需要检验和更新。因此，各组织必须采用基于情境的采购计划，将关税敏感性、供应商资格认证时间表和监管影响评估纳入考量，以确保供应的连续性和治疗的可及性。

将设备类型、最终用户、产品形式、治疗方法和通路与战略产品决策联繫起来的详细細項分析

要使产品开发和商业化策略与临床和营运实际情况相符，对细分市场动态的深入理解至关重要。依设备类型分析，竞争格局涵盖自动注射器、植入式帮浦、输液帮浦、微流体装置、无针注射器、预填充式注射器和传统注射器，每种产品在精准给药、便携性和监管复杂性之间各有重点。同样，按最终用户分析也揭示了诊所、居家医疗机构、医院和专科护理中心的不同需求。医院需要整合的设备生态系统和高通量可靠性，而居家医疗和专科护理中心则更注重易用性、紧凑的外形尺寸和远端监控功能。

产品类型细分突显了具有生命週期服务的可重复使用系统与一次性抛弃式之间的区别，后者简化了灭菌管理并降低了交叉污染风险，指南维护基础设施和单位经济效益方面的选择。治疗方法区分了细胞疗法和基因疗法。在细胞疗法中，CAR-T 疗法、树突细胞疗法和干细胞疗法各自对操作、给药途径和时间限制各有不同；而基因疗法则区分了非病毒载体和病毒载体策略，这会影响到控制措施、给药准确性和监管申报结构。分销管道的差异——医院药房、线上药房和零售药房——进一步细分，其中线上药房分为通讯模式和传统线上模式，零售药房分为连锁店和独立门市。这突显了不同管道在物流、低温运输要求和护理点协调方面的差异。整合这些细分观点有助于制定有针对性的产品蓝图和分销策略，从而反映实际应用情境和相关人员的偏好。

本文从实际角度检验了区域法规环境、基础设施建设和医疗服务模式如何影响医疗设备的采用和普及。

区域趋势对医疗器材策略、监管互动和商业化执行有着深远的影响。有效的规划需要针对不同区域采取差异化的方法。在美洲，临床试验活动、集中化的卓越中心以及不断完善的医保报销环境，都为创新医疗解决方案的快速普及提供了支持。然而，清晰的报销路径和支付方参与对于更广泛的应用仍然至关重要。欧洲、中东和非洲地区（EMEA）的监管环境各不相同，各国医疗设备框架和采购模式的差异，要求制定适应性强的监管策略和区域性的价值提案。然而，在某些司法管辖区，集中采购和与公共医疗系统合作蕴藏着巨大的机会。亚太地区正在经历快速发展的创新中心、不断完善的医院基础设施以及对分散式医疗模式日益增长的关注，但相关人员必须克服因市场而异的监管时间表和物流挑战。

无论在哪个地区，在专业中心之外使用复杂生物製药製剂的可行性取决于低温运输基础设施的成熟度、医疗卫生人力能力以及患者获取途径的完善程度。因此，企业应优先考虑针对特定地区的证据产生、为临床医生和看护者定制的培训项目，以及与当地药房和医院采购惯例相符的经销伙伴。制定一项结合全球标准和本地适应性的协调一致的区域策略，对于在确保品质和患者安全的同时扩大先进疗法的应用规模至关重要。

深入剖析製造商、创新者和服务供应商如何调整营运和合作关係，以加速医疗设备辅助治疗方法的普及应用。

主要企业的行动正朝着几个战略要务汇聚，这些要务将影响它们在给药装置领域的竞争地位。成熟的医疗技术公司正利用其深厚的监管经验、生产规模和分销网络，拓展至专业给药系统领域，并经常与治疗方法开发商寻求合作和授权，以打造整合组合产品。同时，敏捷的Start-Ups和装置创新者正透过平台技术实现差异化，例如模组化注射架构、紧凑型微流体处理器和感测器驱动的自动注射器，这些技术能够解决特定的临床难题，并实现人体工学和连接功能的快速改进。

合约研发生产机构 (CDMO) 提供无尘室设施、可扩展的组装和灭菌服务，在一次性使用产品和复杂组合产品领域发挥日益重要的作用。同时，专注于低温运输物流和检验的运输系统的公司正成为治疗方法申办方寻求可预测的交付时间和温度敏感型生物製药可追溯性的策略合作伙伴。在整个生态系统中，成功的企业正在采用协作式市场推广策略，投资早期监管对话，并优先进行严格的人体工学研究，以降低实施风险。竞争优势越来越依赖于展现产品在实际应用中的可靠性、与临床工作流程的互通性以及上市后资料收集能力，以支援持续的安全性和效能监测。

为医疗设备开发商和治疗方法赞助商提供切实可行的、优先排序的策略建议，以协调创新、供应链韧性和监管准备。

为了最大限度地发挥先进生物製剂的治疗和营运价值，产业领导者应采取将器械创新与临床工作流程、监管策略和商业性执行相结合的方法。首先，在设计过程早期就应纳入人体工学和临床医生参与，以确保器械满足所有给药环境（包括医院、专科中心、诊所和家庭配送）的实际限制。这种早期调整可以减少返工并加快监管核准。其次，应建立多元化的供应链，利用合格的二级供应商和关键零件的近岸外包选项，以在降低关税和前置作业时间风险的同时，保持严格的品管。

第三，组成跨职能团队，成员包括监管、转化研究、生产和商业等相关人员，以指导联合用药产品的核准途径，并制定上市后监测和真实世界资料收集计画。第四，投资数位化（互联互通、远端监测和分析），以提高病患依从性，及早发现安全讯号，并向支付者和医疗服务提供者展现价值。最后，制定灵活的分销策略，以适应不同管道的差异，包括医院药房、线上和通讯模式、连锁和独立零售网路以及门诊机构。透过实施这些措施，企业可以减少商业化阻力，支持以患者为中心的医疗模式，并建立适应不断变化的治疗模式的弹性运作体系。

透明的混合方法研究结合了直接的专家对话和二手证据综合，确保了研究结果的严谨性和可操作性。

本研究采用混合方法，将质性专家见解与严谨的二次检验结合，以得出可操作的结论。主要数据包括对医疗设备工程师、临床研究人员、药房主任和供应链经理的深入访谈，以及与监管专家的结构化咨询，以了解应用和上市后要求。这些相关人员的对话旨在捕捉有关医疗设备可用性、病毒和非病毒载体控制需求以及医院、诊所、专科护理中心和居家医疗环境中实际工作流程限制等方面的经验细节。

二次分析利用已发布的监管指南、同行评审文献、临床试验註册资讯和供应商技术资料表，以检验的证据支持研究结果。此外，它还整合了具有代表性的医疗设备和治疗方法组合的案例研究，以阐明设计选择、人体工学迭代和物流解决方案。资料三角验证确保结论得到资讯来源支持，并透过记录的假设、访谈指南和检验查核点，使调查方法透明化。此方法始终强调可重复性和相关人员的检验，确保研究结果反映实际操作情况，并为研发、监管和商业等各个环节的实际决策提供依据。

简洁扼要的结论总结了设备创新、营运韧性和相关人员之间的协作将如何决定医疗服务的成功交付。

整体结论显而易见：细胞和基因疗法的成功应用，不仅取决于生物治疗方法本身，也取决于递送系统的设计和物流协调。设备技术的创新，加上数位化连接和自适应分销模式的进步，正在加速复杂治疗方法的去中心化，同时也提高了对人为因素、低温运输管理和监管协调的要求。同时，关税政策的波动和区域基础设施的差异等外部因素，也要求制定积极主动的供应链策略和在地化的商业化方案。

儘早整合跨职能团队、优先考虑以使用者为中心的迭代设计并积极与监管机构沟通的组织，将能够降低技术和商业性风险。此外，有效整合设备和治疗方法需要製造商、合约合作伙伴、物流专家和医疗服务提供者等日益壮大的生态系统之间的协作。最终，能否实现可扩展、安全且以患者为中心的先进生物製剂交付，将取决于相关人员在产品生命週期内协调技术卓越性、运营韧性和循证实践的能力。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合用于可扩展CAR-T细胞生产的封闭式自动化微流体系统
  • 开发一种可穿戴生物感测器设备，实现对基因治疗递送的即时监测
  • 皮肤科局部基因编辑中无针电穿孔贴片的应用
  • 用于局部细胞和基因传递的可生物降解水凝胶支架植入的研究进展
  • 引入人工智慧驱动的设计软体来优化病毒载体，以提高基因治疗的安全性
  • 携带式冷冻保存装置的出现，为分散式、按需CAR-T细胞和干细胞保存提供了可能。
  • 扩展3D生物列印系统，以实现直接原位组织工程和标靶基因递送
  • 利用微针阵列贴片实现基于 CRISPR 的基因疗法的无痛皮内递送

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按设备类型分類的细胞和基因治疗药物传输设备市场

  • 自动注射器
  • 植入式帮浦
  • 点滴帮浦
  • 微流体控装置
  • 无针注射器
  • 预填充式注射器
  • 注射器

9. 按最终用户分類的细胞和基因治疗药物传输设备市场

  • 诊所
  • 居家医疗
  • 医院
  • 专业医疗机构

第十章：按产品类型分類的细胞和基因治疗药物输送装置市场

  • 可重复使用的
  • 一次使用

第十一章 细胞与基因疗法药物传递装置市场（依治疗方法）

  • 细胞疗法
    • CAR-T疗法
    • 树突细胞疗法
    • 干细胞疗法
  • 基因治疗
    • 非病毒载体
    • 病毒载体

第十二章 细胞与基因治疗药物输送装置市场（依分销管道划分）

  • 医院药房
  • 网路药房
    • 通讯药房
    • 传统药房及网上药房
  • 零售药房
    • 连锁药局
    • 独立药房

第十三章 细胞与基因治疗药物传递装置市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 细胞与基因治疗药物传递装置市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国细胞及基因治疗药物传递装置市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Becton, Dickinson and Company
    • Terumo Corporation
    • B. Braun Melsungen AG
    • ICU Medical, Inc.
    • West Pharmaceutical Services, Inc.
    • Gerresheimer AG
    • Ypsomed Holding AG
    • Catalent, Inc.
    • Fresenius SE & Co. KGaA
    • MaxCyte, Inc.
Product Code: MRR-5C6F41F5AF95

The Cell & Gene Therapy Drug Delivery Devices Market is projected to grow by USD 2.57 billion at a CAGR of 10.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.17 billion
Estimated Year [2025] USD 1.29 billion
Forecast Year [2032] USD 2.57 billion
CAGR (%) 10.29%

A forward-looking introduction that frames the technical, clinical, and regulatory imperatives shaping delivery device strategies for advanced biologics

The convergence of advanced biologics and precision delivery devices is reshaping how clinicians and healthcare systems approach complex therapies. Recent innovations in device engineering, materials science, and connectivity have created new opportunities to improve dosing accuracy, patient adherence, and safety for cell and gene therapies. At the same time, clinical program requirements for handling living cells and genetic vectors impose exacting constraints on device compatibility, cold chain logistics, and aseptic administration, demanding a fresh evaluation of product design and operational workflows.

Stakeholders across product development, clinical operations, and commercial strategy now face a bifurcated challenge: integrate enabling delivery technologies that preserve therapeutic integrity while minimizing complexity for end users, and simultaneously navigate increasingly stringent regulatory expectations for combination product evaluation. These dynamics have elevated cross-disciplinary collaboration as a critical success factor, with engineers, translational scientists, and regulatory experts needing to converge earlier in development cycles. As a result, organizations that prioritize integrated device-therapy development, robust human factors engineering, and clear regulatory engagement pathways are better positioned to advance clinical adoption and scale treatment delivery.

A comprehensive exploration of the major transformative trends in device technology, decentralized care, and regulatory convergence redefining therapeutic delivery

The landscape for cell and gene therapy delivery devices is undergoing transformative shifts driven by parallel advances in therapy complexity, patient-centric care models, and digital health integration. Therapy developers increasingly prioritize minimally invasive delivery and outpatient administration, prompting device makers to innovate with autoinjectors, needle-free injectors, microfluidic systems, and wearable infusion platforms that reduce clinic dependency. At the same time, the trend toward decentralized care has accelerated investment in devices that are intuitive for home use while maintaining chain-of-custody and environmental controls for sensitive biologics.

Concurrently, manufacturing and supply chain sophistication are rising to meet the demands of personalized and batch-limited therapies. Microfluidic devices and modular infusion systems are being explored to enable localized processing and point-of-care manipulation of cell products, which could shorten critical timelines between harvest, manipulation, and delivery. Regulatory authorities are adapting guidance to address combination products and the intersection of device and biologic review, which is prompting more proactive engagement between sponsors and regulators. Moreover, digital connectivity and remote monitoring capabilities are being embedded into devices to provide real-time adherence and safety data, supporting iterative improvements in therapy protocols and post-market surveillance. Taken together, these shifts create both opportunities and complexities, and organizations must adopt integrated development pathways and robust stakeholder collaboration to capitalize on the evolving environment.

A strategic assessment of how cumulative tariff measures through 2025 are reshaping procurement, sourcing, and manufacturing resilience for delivery systems

The introduction of new tariff measures affecting imported medical components and finished devices is exerting measurable pressure on the supply chains that underpin cell and gene therapy delivery systems. Cumulative tariff actions enacted through 2025 have increased costs for certain upstream raw materials, specialized polymers, and precision components used in autoinjectors, infusion pumps, and single-use disposables. As a consequence, procurement teams are recalibrating supplier portfolios, exploring alternative sources, and reassessing total landed cost models to maintain program viability and pricing transparency.

In response, many manufacturers have initiated dual strategies of supplier diversification and nearshoring where feasible, seeking to minimize exposure to tariff volatility and reduce lead times for critical components. These approaches lead to trade-offs: relocating production can reduce tariff risk but may require capital investment, workforce training, and new quality system validations. Additionally, tariff-driven cost increases have implications for contract manufacturing negotiations and long-term supply agreements, elevating the importance of clear commercial terms, risk-sharing structures, and contingency planning.

Regulatory compliance and traceability requirements further complicate mitigation efforts, as sourcing alterations necessitate revalidation and potential device submission updates. Therefore, organizations must adopt scenario-based procurement planning that integrates tariff sensitivity, supplier qualification timelines, and regulatory impact assessments to preserve continuity of supply and maintain treatment accessibility.

A detailed set of segmentation insights linking device types, end users, product formats, therapy modalities, and distribution pathways to strategic product decisions

A nuanced understanding of segmentation dynamics is essential for aligning product development and commercialization strategies with clinical and operational realities. When studied by device type, the competitive landscape spans autoinjectors, implantable pumps, infusion pumps, microfluidic devices, needle-free injectors, pre-filled syringes, and conventional syringes, each offering distinct trade-offs between precision dosing, portability, and regulatory complexity. Likewise, analysis by end user highlights divergent needs across clinics, homecare settings, hospitals, and specialty centers; hospitals demand integrated device ecosystems and high-throughput reliability, while homecare and specialty centers prioritize ease of use, compact form factors, and remote monitoring capabilities.

Product type segmentation emphasizes the contrast between reusable systems that support lifecycle servicing and single-use disposables that simplify sterility and reduce cross-contamination risk, informing choices around maintenance infrastructure and unit economics. Therapy type segmentation divides the space into cell therapy and gene therapy; within cell therapy, CAR-T therapies, dendritic cell approaches, and stem cell treatments each impose unique handling, administration route, and timing constraints, whereas gene therapy pathways differentiate non-viral vector and viral vector strategies with implications for containment, dosing accuracy, and regulatory dossier composition. Distribution channel distinctions among hospital pharmacy, online pharmacy, and retail pharmacy, with online pharmacy further split into mail order and traditional online models and retail pharmacy further differentiated between chain and independent outlets, underscore how logistics, cold chain requirements, and point-of-care coordination vary by pathway. Integrating these segmentation perspectives enables targeted product roadmaps and distribution strategies that reflect real-world use cases and stakeholder preferences.

A pragmatic examination of how regional regulatory environments, infrastructure maturity, and healthcare delivery models influence device deployment and adoption

Regional dynamics exert a profound influence on device strategy, regulatory engagement, and commercialization execution, and effective planning requires a regionally differentiated approach. In the Americas, clinical trial activity, concentrated centers of excellence, and a progressive reimbursement environment support rapid adoption of novel delivery solutions, while reimbursement pathway clarity and payer engagement remain critical for broader uptake. Europe, the Middle East & Africa present a heterogeneous regulatory landscape, where varying national device frameworks and divergent procurement models necessitate adaptive regulatory strategies and localized value propositions; this region also offers strong opportunities for centralized procurement and collaborations with public health systems in certain jurisdictions. Asia-Pacific combines rapid innovation hubs, expanding hospital infrastructure, and an increasing focus on decentralized care models, but stakeholders must navigate diverse regulatory timelines and logistics challenges across markets.

Across regions, cold chain infrastructure maturity, healthcare workforce capacity, and patient access models shape the practical viability of complex biologic administrations outside specialized centers. Therefore, companies must prioritize region-specific evidence generation, tailored training programs for clinicians and caregivers, and distribution partnerships that align with local pharmacy and hospital procurement practices. Coordinated regional strategies that balance global standards with local adaptability will be essential to scale advanced therapies while ensuring consistent quality and patient safety.

An incisive look at how manufacturers, innovators, and service providers are aligning operations and partnerships to accelerate device-enabled therapy adoption

Key corporate behaviors are converging around several strategic imperatives that influence competitive positioning in the delivery device segment. Established medtech firms are leveraging deep regulatory experience, manufacturing scale, and distribution networks to expand into specialty delivery systems, frequently pursuing partnerships or licensing arrangements with therapy developers to create integrated combination products. At the same time, agile startups and device innovators are differentiating through platform technologies-such as modular infusion architectures, compact microfluidic processors, and sensor-enabled autoinjectors-that address specific clinical pain points and enable faster iteration of human factors and connectivity features.

Contract development and manufacturing organizations play an increasingly central role, offering clean-room capacity, scalable assembly, and sterilization services that are essential for single-use disposables and complex combination products. Meanwhile, companies specializing in cold chain logistics and validated transport systems are becoming strategic partners for therapy sponsors seeking predictable delivery windows and traceability for temperature-sensitive biologics. Across the ecosystem, successful players adopt collaborative go-to-market strategies, invest in early regulatory dialogue, and prioritize rigorous human factors studies to de-risk adoption. Competitive differentiation increasingly hinges on the ability to demonstrate real-world reliability, interoperability with clinical workflows, and post-market data collection capabilities that support ongoing safety and performance monitoring.

A practical and prioritized set of strategic recommendations for device developers and therapy sponsors to align innovation, supply resilience, and regulatory readiness

Industry leaders should pursue an integrated approach that aligns device innovation with clinical workflow, regulatory strategy, and commercial execution to capture the full therapeutic and operational value of advanced biologics. First, embed human factors and clinician engagement early in the design process to ensure devices meet practical constraints of administration environments, whether in a hospital, specialty center, clinic, or the home. This early alignment reduces rework and accelerates regulatory acceptance. Second, cultivate diversified supply chains with qualified secondary suppliers and nearshoring options for critical components to mitigate tariff exposure and lead-time risk while maintaining robust quality governance.

Third, establish cross-functional teams that include regulatory, translational, manufacturing, and commercial stakeholders to navigate combination product pathways and to plan for post-market surveillance and real-world evidence collection. Fourth, invest in digital enablement-connectivity, remote monitoring, and analytics-to enhance adherence, detect early safety signals, and provide evidence of value to payers and providers. Finally, develop flexible distribution strategies that reflect differences across hospital pharmacies, online and mail order models, chain and independent retail networks, and outpatient care settings. By implementing these actions, organizations can reduce commercialization friction, support patient-centric care models, and build resilient operations that accommodate evolving therapy paradigms.

A transparent mixed-methods research approach combining primary expert engagements and secondary evidence synthesis to ensure rigorous and actionable insights

This research employs a mixed-methods approach that synthesizes qualitative expert insight with rigorous secondary validation to produce actionable findings. Primary inputs include in-depth interviews with device engineers, clinical investigators, pharmacy directors, and supply chain executives, combined with structured consultations with regulatory specialists to understand submission and post-market requirements. These stakeholder engagements are designed to capture experiential nuances around device usability, containment needs for viral and non-viral vectors, and real-world workflow constraints across hospitals, clinics, specialty centers, and homecare environments.

Secondary analysis draws on publicly available regulatory guidance, peer-reviewed literature, clinical trial registries, and supplier technical datasheets to ground findings in verifiable evidence. The research also integrates case study reviews of representative device-therapy pairings to illustrate design choices, human factors iterations, and logistics solutions. Data triangulation ensures conclusions are corroborated across multiple sources, and methodological transparency is maintained through documented assumptions, interview guides, and validation checkpoints. Throughout, the approach emphasizes reproducibility and stakeholder validation to ensure that insights reflect operational realities and inform practical decision-making across development, regulatory, and commercial functions.

A concise conclusion synthesizing how device innovation, operational resilience, and stakeholder collaboration determine successful therapy delivery outcomes

The cumulative narrative is clear: successful deployment of cell and gene therapies depends as much on delivery system design and logistical orchestration as it does on the biological modality itself. Innovations in device technology, coupled with digital connectivity and adaptive distribution models, are enabling broader decentralization of complex therapies while elevating requirements for human factors, cold chain management, and regulatory coordination. At the same time, external forces such as tariff policy shifts and regional infrastructure disparities necessitate proactive supply chain strategies and localized commercialization approaches.

Organizations that integrate cross-functional teams early, prioritize iterative user-centered design, and engage regulators proactively will reduce technical and commercial risk. Moreover, the effective pairing of device and therapy demands collaboration across a growing ecosystem of manufacturers, contract partners, logistics specialists, and healthcare providers. Ultimately, the path to scalable, safe, and patient-centric delivery of advanced biologics will be determined by the ability of stakeholders to harmonize engineering excellence, operational resilience, and evidence generation throughout the product lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of closed automated microfluidic systems for scalable CAR-T cell manufacturing
  • 5.2. Development of wearable biosensor devices for real-time monitoring of gene therapy delivery
  • 5.3. Adoption of needle-free electroporation patches for in situ gene editing in dermatological applications
  • 5.4. Advancement of biodegradable hydrogel scaffold implants for localized cell and gene delivery
  • 5.5. Implementation of AI-driven design software in viral vector optimization for improved gene therapy safety
  • 5.6. Emergence of portable cryopreservation units for decentralized on-demand CAR-T and stem cell storage
  • 5.7. Expansion of 3D bioprinter systems for direct in situ tissue engineering and targeted gene incorporation
  • 5.8. Use of microneedle array patches for pain-free intradermal delivery of CRISPR-based gene therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Drug Delivery Devices Market, by Device Type

  • 8.1. Autoinjector
  • 8.2. Implantable Pump
  • 8.3. Infusion Pump
  • 8.4. Microfluidic Device
  • 8.5. Needle-Free Injector
  • 8.6. Pre-Filled Syringe
  • 8.7. Syringe

9. Cell & Gene Therapy Drug Delivery Devices Market, by End User

  • 9.1. Clinic
  • 9.2. Homecare
  • 9.3. Hospital
  • 9.4. Specialty Center

10. Cell & Gene Therapy Drug Delivery Devices Market, by Product Type

  • 10.1. Reusable
  • 10.2. Single Use

11. Cell & Gene Therapy Drug Delivery Devices Market, by Therapy Type

  • 11.1. Cell Therapy
    • 11.1.1. CAR-T Therapy
    • 11.1.2. Dendritic Cell Therapy
    • 11.1.3. Stem Cell Therapy
  • 11.2. Gene Therapy
    • 11.2.1. Non-Viral Vector
    • 11.2.2. Viral Vector

12. Cell & Gene Therapy Drug Delivery Devices Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
    • 12.2.1. Mail Order Pharmacy
    • 12.2.2. Traditional Online Pharmacy
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain Pharmacy
    • 12.3.2. Independent Pharmacy

13. Cell & Gene Therapy Drug Delivery Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Drug Delivery Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Drug Delivery Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Becton, Dickinson and Company
    • 16.3.2. Terumo Corporation
    • 16.3.3. B. Braun Melsungen AG
    • 16.3.4. ICU Medical, Inc.
    • 16.3.5. West Pharmaceutical Services, Inc.
    • 16.3.6. Gerresheimer AG
    • 16.3.7. Ypsomed Holding AG
    • 16.3.8. Catalent, Inc.
    • 16.3.9. Fresenius SE & Co. KGaA
    • 16.3.10. MaxCyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SI